Precigen Inc
PGENHealthcare|Biotechnology|USA
$5.33
-0.21 (-3.80%)
Tangible Book
$0.01
Upcoming Data Readouts (2)
Nov 2026
Est. completion
P2Cervical Cancer
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151n=24
Dec 2027
Est. completion
P4Recurrent Respiratory Papillomatosis
Zopa Retreatment and Vector Shedding in Adults With RRP
NCT06538480n=30
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Dec 2024
P1
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527Aug 2024
P1
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
NCT03927261Jun 2024
P1P2
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
NCT04724980